Stroke and atrial fibrillation in sick sinus syndrome After the first electrocardiographic description of sinus node disease in 1923 by Wenckebach, it took about 50 years until the clinical entity of sinus node disorder, including its electrocardiographic parameters and clinical symptoms, was established. Currently between 40% and 50% of patients in Europe and the United States that receive a pacemaker have sinus node disease as the underlying rhythm disorder. Of those, 20% to 30% have had symptoms of paroxysmal or intermittent atrial fibrillation as part of the sinus node disorder. This entity is also called brady-tachy syndrome.
This syndrome, which was first described in 1968, summarises various manifestations of sinoatrial rhythm disorders: * serious, persistent, otherwise inexplicable sinus bradycardias that often represent the initial symptom;
* sinus arrest with replacement of the sinus rhythm by heterotopic atrial or nodal rhythms, or long periods of cardiac arrest in situations in which the latter fail; * paroxysmal or chronic atrial fibrillation due to sinus arrest; * an inadequate sinus node activity post-cardioversion of atrial fibrillation; * sinoatrial exit blocks unrelated to medical treatments; * inadequate heart rate increase during incremental exercise. The activity of the sinus node, which consists of four different cell types capable of engendering sinus node automaticity, is conducted to the atrioventricular node via three physiological pathways (James, Wenckebach, and Thorel). The content of sinus node cells involved in normal impulse formation has been shown to diminish with advanced age, but without causing serious damage to the function of the sinus node unless more than 90% of the content is destroyed. Additional mechanisms forming the anatomical basis of sinus node syndrome are destruction of the sinus node itself or of nodoatrial areas resulting from-for example, ischaemia, inflammatory or degenerative changes of the nerves and ganglia surrounding the sinus node, and pathological changes in the atrial myocardial wall such as fibrosis or fatty infiltration, all of which lead to dispersion of refractoriness and to a decrease in conduction velocity. Consequently, heterotopic atrial or nodal rhythms emerge depriving an otherwise normal heart of its active atrial contraction during the cardiac cycle. A 4 Recent trials on anticoagulation, especially low dose warfarin, in patients with atrial fibrillation have focused attention on the morbidity and mortality associated with atrial fibrillation. Strokes were reduced from 3-7 4% annually without treatment to 04-2-6% with treatment, a considerable therapeutic benefit.
Retrospective trials linking pacing and sick sinus syndrome with complications The first study that showed that the mode of pacing in patients with sick sinus syndrome had an effect on mortality and morbidity was that of Rosenqvist et al.6 In this study, 168 patients with sick sinus syndrome treated at two hospitals in Sweden received either a VVI system at one hospital or an AAIR pacemaker at the other. Both groups had similar baseline clinical characteristics, characteristics of sinus node disorder, or prior intermittent atrial tachyarrhythmias. At a mean follow up of four years, 4% of the patients with an AAIR pacemaker developed chronic atrial fibrillation compared with 39% of patients with the VVI system. There was also a slight significant difference in the development of congestive heart failure (7% v 23%) and the incidence of stroke (4-5% v 13%). Whatever type of pacemaker was implanted, the incidence of cerebrovascular disease and stroke was 23% in the patients who developed chronic atrial fibrillation and 6% in patients who remained in sinus rhythm.
This first study triggered similar investigations that analysed the dataset from larger patient populations. Hesselson et al analysed data from 950 pacemaker implants over a period of seven years and found a significant increase in the development of chronic atrial fibrillation in patients in whom a VVI pacemaker was implanted compared with patients in whom a physiological DDD or WD system was implanted.7 The incidence of atrial fibrillation was highest in patients with sick sinus syndrome and a prior history of atrial fibrillation. Concomitantly, patients older than 70 years had an extraordinarily high likelihood of developing atrial fibrillation if they received a VVI pacemaker for treatment of sick sinus syndrome. This is particularly important as this group may not be as easy or safe to treat with anticoagulation.
A study from the Cleveland Clinic8 analysed the outcome in 507 patients with sick sinus syndrome with respect to two end points: development of chronic atrial fibrillation and the incidence of stroke. The incidence of atrial fibrillation was 7% at one year, 16% at five years, and 28% at 10 years; the incidence of stroke was 30% at 10 years. Independent risk factors for chronic atrial fibrillation were a history of paroxysmal atrial fibrillation (hazard ratio , ventricular pacing mode (hazard ratio 1-98), age, and heart valve disease. Independent predictors of stroke were ventricular pacing mode (hazard ratio 2-6) and a history of paroxysmal atrial fibrillation (hazard ratio 2 8).
The mortality and stroke in patients with sick sinus syndrome with respect to pacing system was also highlighted in a recent study by Santini et al. 9 They not only found an incidence of 47% of chronic atrial fibrillation in patients treated with VVI pacemakers, but also a significantly increased mortality of 8% v 2-5% from stroke in patients with VVI compared with patients with AAI or DDD pacemakers. Similar to the paper from Hesselson et al that showed that patients older than 70 years have a significantly higher risk of experiencing a fatal stroke,7 Santini et al observed that there was a stroke mortality of 16% v 3% in patients with a VVI compared with a physiological system. 9 The abundance of retrospective literature regarding pacing mode, development of chronic atrial fibrillation, and the incidence of thromboembolism has been amplified by recent summaries compiled by Rosenqvist et al, 6 Sutton and Kenny,'0 and Camm and Katritsis" who compared the data from different studies. These reports showed that the annual incidence of atrial fibrillation among all the studies was 5-15% for VVI and 1-3% for AAI. In the analysis by Camm and Katritsis," the incidence of thromboembolism in sick sinus syndrome treated with VVI pacing ranged from 10% to as high as 48%.
Prospective studies There are currently only two prospective trials investigating the outcome depending on pacing mode in sick sinus syndrome and atrial fibrillation. The trial by Andersen et al"2 analysed 225 consecutive patients that were followed up for five years. Patients with sick sinus syndrome had been randomised to either atrial or ventricular pacing. During follow up, the frequency of atrial fibrillation was higher in the ventricular paced group; thromboembolic events occurred in 20 patients (17%) in the ventricular group versus six (5%) with atrial pacing (P < 0-008). Twenty five patients (22%) died in the ventricular group compared with 21 (19%) in the atrial group. While this study found a significant difference regarding occurrence of atrial fibrillation and stroke, the two pacing mode groups exhibited no significant difference in mortality.
Similar results were reported in a recent study by Lamas et al."3 In their preliminary PASE study (PAcemaker Selection in the Elderly), a multicentre, prospective, randomised trial, 403 patients with sick sinus syndrome were randomised to either VVI or DDDR pacing. At one year follow up, mortality was 12% in the VVIR group versus 6% in the DDDR group, incidence of stroke was 4% versus 2%, and combined events were 19% and 10%, respectively. For patients with AV block, the death rate was 10% v 9%, stroke 2% v 0%, and combined events 19% v 13%. While none of these events reached the level of significance, there was an unambiguous trend towards higher death rate and higher stroke occurrence in patients with sick sinus syndrome in VVIR. For patients with AV block virtually no difference with respect to mortality was evident; however, strokes and combined events occurred more frequently in the VVIR paced group.
Limitations and criticisms A recent paper'4 expresses considerable criticism regarding the analysis of retrospective data. In this analysis of more than 38 000 patient files from the Medicare/ Medicaid database, a significant selection bias was found regarding the type of pacemaker. While it is true that in clinical practice it is more likely that patients who are older or sicker, or have compromised myocardial function, are more likely to receive a single chamber than a dual chamber pacemaker, the point made in these retrospective and prospective studies that a higher incidence of stroke and death from stroke are observed among patients paced VVI for sick sinus syndrome cannot be discarded. Currently, the general practice of pacing differs considerably between Europe and the United States. In Europe the use of physiological pacemakers ranges between 20% and 30%, in the United States the range is 50% to 70%. Therefore, it is not surprising that in the United States some criticism on the use of high end products has been expressed concerning their use in patients for whom physiological pacing might have only marginal benefit. The hypothetical case that may best highlight this is the patient with sinus node disorder and intermittent atrial fibrillation who receives a sophisticated DDDR pacemaker. The patient develops chronic atrial fibrillation a few days after implant and spontaneous healing of the sinus node syndrome without the need of a pacemaker for the rest of his or her life as AV conduction is not compromised. In this patient, the implantation of a DDDR device is of little benefit. At present, there is a lack of convincing prospective studies that indicate which patient with sick sinus syndrome would best be treated with which mode of pacing. In addition to conventional atrial and ventricular pacing, new forms of treatment have been developed over the past few years, for example, the dual site pacing described by the Saksena group'5 and by Claude Daubert et al. '6 Both have shown that in a certain type of sinus node disorder with paroxysmal atrial fibrillation, the stimulation of the atrium from two sides may be beneficial in reducing the recurrence of atrial fibrillation. Other new forms of treatment include the electrical ablation of the atrium to prevent atrial fibrillation in the form of an electrical corridor similar to the maze operation, and the implantation of an atrial defibrillator that shocks patients back to sinus rhythm; however, these are all under clinical investigation.
In contrast, medical treatment does not appear to confer relevant benefit with respect to long term stabilisation of the disease as, although the occurrence of atrial fibrillation can be prevented in a meaningful percentage of cases at least for some time, the natural course of the syndrome and its manifestations have to be taken into consideration.
Current selection criteria
Though new forms of treatment are on the verge of clinical investigation, current modes of treatment should be based on established clinical wisdom. Surely, a patient with sick sinus syndrome, constant sinus bradycardia, and retrograde atrial-ventricular conduction will presumably derive little benefit from the implantation of a pure VVI pacemaker, while a patient with sick sinus syndrome and infrequent, intermittent sinoatrial block that clinically manifests as intermittent syncope may be provided with a VVI pacemaker programmed to a low hysteresis rate. In patients in whom intermittent atrial fibrillation is present, the use of atrial pacing can help to establish antiarrhythmic treatment. If a patient has a long history of atrial fibrillation, considerable enlargement of the atria, and coronary artery disease with fibrosis in the atria, the long term chances of maintaining sinus rhythm may be low; this patient may fare better long term with low dose warfarin and a ventricular pacing system. Atrial pacing should be the norm in patients with sick sinus syndrome, even in the elderly, as in this group the incidence of atrial fibrillation with VVI pacing is higher, the incidence of thromboembolic complications with atrial fibrillation is higher, and the difficulties associated with warfarin therapy are so high that the benefit compared with aspirin is less than clear. However, there are economic issues that argue against the routine use of dual chamber pacemakers. These are usually selected because of lack of confidence in atrioventricular conduction in these patients. However, this is not supported by clinical data, for example in the Danish study12 the need for upgrading from AAI to DDD was very low (a Wenckebach point was measured at implant). Perhaps we should consider more systematic use of AAI rather than dual chamber pacing in sick sinus syndrome.
In addition to currently available data,17 the outcome of randomised prospective studies, such as PASE and MOSSST (MOdes Switch Selection STudy), which will include more than 2000 patients with sick sinus syndrome, will shed more light on the benefits and risks of individual pacing therapies for sick sinus syndrome in light of additional clinical variables. Based on the data we received from the anticoagulation studies, the use of low dose warfarin currently provides a powerful means of reducing stroke and mortality in patients with paroxysmal and chronic atrial fibrillation.'8 With the forces of our changes in reimbursement and economic constrictions, the demonstration of a clinical benefit and cost effectiveness will be needed for justifying a widespread use of more than 50% dual chamber pacemakers. Perhaps the simple AAI pacemaker favoured in Europe (particularly in Scandinavia with excellent results) but less so in other countries (presumably due to liability reasons and assumed uncertainties regarding the development of atrioventricular conduction disturbances in the further course of the syndrome), may be a cost effective solution to some of the problems without anticipating the results of the prospective, randomised multicentre studies that will be completed between 1998 and 2000.
